EndoGastric Solutions, Inc. Completes Patient Enrollment in Clinical Trial Comparing TIF Procedure to PPI Therapy for the Treatment of GERD
10/2/2012 10:11:13 AM
REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), the leader in endoluminal treatment of Gastroesophageal Reflux Disease (GERD), today announced the completion of enrollment in its Transoral Incisionless Fundoplication (TIF®) versus Medical Proton Pump Inhibitor (PPI) Management of Refractory GERD Symptoms (TEMPO) clinical trial, which will generate U.S. Level I evidence for TIF. The trial is designed to assess the safety and efficacy of the TIF procedure as compared to PPI therapy to treat bothersome symptoms associated with chronic GERD.
comments powered by